AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04413188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm foot bath
Description: The participants in experimental group were asked to soak their feet in warm water (38-40°C) for 20 minutes one hour before their bedtimes for six weeks. A special foot bath (Beurer FB50 luxury foot bath spa with water heater) was used for this purpose. The bath is 10 cm deep; it keeps water at a constant temperature of 35-48°C for 15-60 minutes, has a display screen for water temperature and duration of use, and turns off automatically.
Study NCT03374228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Specified Dose on Specified Days
Study NCT03223129 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance tests were glucose is administrated orally with an increasing load (25g, 75g, 100 g)
Study NCT00442507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT00442507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Study NCT03471884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonintubated thoracoscopic lobectomy
Description: Nonintubated general anesthesia using fentanyl, target-controlled infusion of propofol to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a spontaneous breathing due to iatrogenic pneumothorax.
Study NCT03471884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubated thoracoscopic lobectomy
Description: Intubated general anesthesia using 2%-3% sevoflurane and rocuronium to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a endobronchial tube or blocker with use of mechanical ventilation.
Study NCT04313985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tennant Biomodulator-Pro™ Device
Description: Tennant Biomodulator-Pro™ conductive electrode pads will be placed on both sides of the wound. The device will either deliver electrical stimulation or no stimulation depending on treatment period.
Study NCT04313985 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Tennant Biomodulator-Pro™ Device
Description: Tennant Biomodulator-Pro™ conductive electrode pads will be placed on both sides of the wound. The device will either deliver electrical stimulation or no stimulation depending on treatment period.
Study NCT01082159 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: lumbar decompression
Description: The mild® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
Study NCT00788606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab, Rituximab
Description: 6 cycles of treatment. Bevacizumab at a dose of 15 mg/kg, diluted in normal saline will be administered as a intravenous infusion over 30 to 90 minutes on Day 1 of each cycle. Rituzimab 375 mg/m2 is given as a intravenous infusion after the administration of prednisolone and before the other cytotoxic drugs on Day 1 of each cycle.
Study NCT04432415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: Annual application od Silver Diamine Fluoride
Study NCT04432415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soduim Fluoride Varnish
Description: biannual apllication of Sodium Fluoride Varnish
Study NCT04432415 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: biannual application of artificial saliva
Study NCT03902626 — intervention group
Intervention type: OTHER
Intervention: Physiotherapy students
Study NCT03902626 — intervention group
Intervention type: OTHER
Intervention: Medical students
Study NCT01575704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised exercise training (aerobic, resistance, flexibility), 5 times per week
Study NCT01575704 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mental Training
Description: Memorial/ mental training and relaxation, 5 times per week
Study NCT03731741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: a known drug of xanthine derivatives used in intermittent claudication
Study NCT01986348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: One cycle is 28 days (4 weeks).
Study NCT02868983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integration
Description: The intervention consists of training for practice leaders, BHCs, PCPs, and office staff, a Protocolized Redesign Process support for practice redesign, and a toolkit of suggested tactics for implementing Tasks A through D:~A. Identification B. Assessment C. Treatment D. Surveillance
Study NCT02429973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus rapamycin
Description: Gemcitabine and rapamycin given in combination
Study NCT01542502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra 100 mg daily subcutaneous injection
Study NCT01542502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily subcutaneous injection
Study NCT02873897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Session A: Experimental products (selected enriched products)
Study NCT02873897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Experimental session: to select enriched products
Study NCT02873897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Session B: Control (standard products without enrichment)
Study NCT02873897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control session
Study NCT02009865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epanova
Description: Epanova will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
Study NCT02009865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: Olive oil will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
Study NCT03768596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vaccination form
Description: a form about vaccination
Study NCT04453930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab，an engineered anti-PD-1 antibody
Description: Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/5/6) and maintenance phase (Cycle onward).
Study NCT04453930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: Carboplatin： Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/5/6).~Cisplatin： Cisplatin intravenous infusion was administered at a dose of 30 milligrams per square meter (mg/m\^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6).
Study NCT04453930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan intravenous infusion was administered at a dose of 65 milligrams per square meter (mg/m\^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6).
Study NCT04453930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib was administered at a dose of 250 mg during the maintenance phase.
Study NCT02935894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg ibuprofen given to inhibit cyclooxygenase metabolism
Study NCT02935894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological induction of sweating
Description: 15 minutes exercise at 60-80% oxygen consumption to induce sweating
Study NCT02935894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine nitrate solution to induce sweating
Study NCT03531892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJM300
Description: AJM300 film-coated tablets.
Study NCT03531892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to AJM300 tablets.
Study NCT01821222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wired mothers
Description: The wired mothers SMS component provided health education and appointment reminders to encourage attendance at routine antenatal care, skilled delivery attendance and postnatal care. A specially-designed software automatically generated and sent text messages throughout the pregnancy until six weeks after delivery. The frequency and content of the messages varied according to the women's gestational age.~Mobile phone vouchers allowed all wired mothers to communicate directly with primary health care providers. Primary health care facilities randomised for intervention and hospitals were provided with a mobile phone with sufficient credit, while wired mothers were given a phone voucher with modest credit and a card with the phone number of her local primary health care provider.
Study NCT04335279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPIN-CHAT Program
Description: Each session will include 3 segments: (1) engagement via therapeutic recreation activities (20-30 minutes); (2) education on information management and anxiety management through psychological and other strategies (20-30 minutes); and (3) open discussion and social support (20-30 minutes). Educational segment topics will include (1) healthy information management and social connection (session 1); (2) managing worry (sessions 2, 6, 10); (3) relaxation strategies (sessions 3; 7, 11); (4) adapted home exercise (sessions 4, 8, 12); and (5) activity engagement at home (sessions 5 and 9). All educational segments will be supported by resource materials available to participants via an online SPIN-CHAT resource link. Supervision and support of group moderators will be provided by a trained social worker. Educational segments in each session will be delivered by a research team member with experience and training related to the topic.
Study NCT02981823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hip replacement
Description: The patients undergo hip replacement with the collum femoris preserving stem suffered from periprosthetic fractures.
Study NCT04779463 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Parasternal intercostal muscles thickness ultrasound indicies
Description: Parasternal intercostal muscles thickness ultrasound indicies includes:~* Parasternal Intercostals Thickness Fraction.~* Parasternal Intercostals Thickness at the End of Inspiration.~* Parasternal Intercostals thickness at the End of Expiration.
Study NCT03547206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPh201 Cohort A
Description: RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
Study NCT03547206 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cohort A
Description: The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene \[BHT\]).
Study NCT01198132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif
Description: Subjects receive subcutaneous injection of Rebif 44 mcg 3 times weekly.
Study NCT01198132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rebif
Description: Subjects receive subcutaneous injection of Rebif 44 mcg 3 times weekly.
Study NCT01308424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTL TML HSV
Description: Sublingual micro-dosing for 7 days
Study NCT01308424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: sublingual dosing for 7 days
Study NCT00839397 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paroxetine
Description: Subjects will take the treatment phase medication once daily after an evening meal. All subjects will be maintained at Dose Level II (20 mg/day) for the first 2 weeks. If a sufficient clinical response (1. Very much improved or 2. Much improved based on the CGI Global Improvement) is achieved, the subject will continue on the same dose level. When the clinical response is not sufficient but the investigational product is well tolerated, the dose will be increased to Dose Level III (30 mg/day) and then to Dose Level IV (40 mg/day) at intervals of at least 2 weeks until a sufficient response is reached. Once a sufficient response is obtained, the treatment will be continued at that dose. The treatment phase will last for a total of 52 weeks. In those patients receiving Dose Level III or IV, dosage reductions to the next lowest level (Dose Level II or III) consequent to an adverse event are permitted.~Dosage adjustment will be made at the discretion of the PI or Sub-PI
Study NCT02836548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: vorinostat 360 milligram once daily
Study NCT02215967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
Study NCT02215967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
Study NCT03547206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPh201 Cohort B
Description: RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
Study NCT03547206 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cohort B
Description: The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene \[BHT\]).
Study NCT01118156 — intervention group
Intervention type: OTHER
Intervention: Education
Description: 75-minute training teaching utilization of new standardized suicide nomenclature
Study NCT04419571 — intervention group
Intervention type: PROCEDURE
Intervention: Emergency Laparotomy
Description: All adult patients undergoing emergency laparotomy
Study NCT03602807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy
Description: 2 treatments a week for 3 weeks consisting of 3000 focused shockwaves of 4Hz and 0,20mJ/mm2 applied over the kidney allograft.~Treatment is performed using the STORZ DUOLITH® SD1 T-TOP F-SW ultra
Study NCT03720028 — intervention group
Intervention type: BEHAVIORAL
Intervention: Observation
Description: Describe communication and sensory profile using standardized tests and observations.
Study NCT03720028 — intervention group
Intervention type: BEHAVIORAL
Intervention: Parental experiences
Description: Survey parents' experiences with parent-child interaction and augmentative and alternative communication.
Study NCT03949959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy
Description: Participants will undertake their usual activities for the 5, 8 or 11 day baseline period following PRP. Participants will begin the 6 week intervention period following this period during which time they will participate in 10 sessions with an experienced postgraduate physiotherapist. After these 6-weeks, participants will have no contact with intervention personnel during the 6-week follow-up period.
Study NCT00704548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 40mg
Description: Simvastatin once daily, orally in the morning period, during eigth weeks
Study NCT00704548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily, orally in the morning period, during eigth weeks
Study NCT00703612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Adipose-derived Stem cells
Description: Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
Study NCT03436537 — intervention group
Intervention type: OTHER
Intervention: Periodontal Aesthetic Perception Scale
Description: Patients answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale
Study NCT00859235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate 0.2%
Description: Mouth wash prior to procedure
Study NCT00859235 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plain water
Description: Mouth wash prior to procedure
Study NCT03407573 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Red Cell
Description: Transfusion of red cells dependent on haemoglobin level. Either transfused at haemoglobin of 7 or 9.
Study NCT04215380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acacia Senegal extract
Description: Oral Digestion of Gum Arabic dissolved in 200 ml of water to be consumed early morning in daily basis for 12 weeks
Study NCT04215380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pectin
Description: Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
Study NCT00629837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)
Description: Low dose of BAY 79-4980 \[13mg of liposomes/kg\] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU).
Study NCT00629837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)
Description: High dose of BAY 79-4980 \[22mg of liposomes/kg\] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU)
Study NCT00629837 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to low dose of BAY 79-4980 \[13mg of liposomes/kg\]
Study NCT00629837 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to high dose of BAY 79-4980 \[22mg of liposomes/kg\]
Study NCT00301210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: oral doses four times per day
Study NCT00725556 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Speech Therapy
Description: Speech Therapy
Study NCT01992861 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo FDG PET/CT
Study NCT01992861 — intervention group
Intervention type: PROCEDURE
Intervention: Diffusion Weighted Imaging
Description: Undergo DW MRI
Study NCT01992861 — intervention group
Intervention type: PROCEDURE
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE MRI
Study NCT01992861 — intervention group
Intervention type: RADIATION
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT
Study NCT01992861 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MR spectroscopy
Study NCT01992861 — intervention group
Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT
Study NCT02955979 — intervention group
Intervention type: OTHER
Intervention: CT scan with iodinated contrast agents
Description: Before the CT scan, the investigators with iodinated contrast agents, the following data will be collected in the medical record: creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern.~After the CT scan the investigators will collect the characteristics of the injection type, osmolarity and volume of contrast used and the appearance of a possible allergic reaction.~Then 24 and 48 hours and day 7 will collect serum creatinine, urine output and vital replacement therapies may be necessary.
Study NCT00644280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly x 2 more injections
Study NCT03830060 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of cortisol
Description: Cortisol will be measured by immunofluorescence and correlated with ANA and hs-CRP
Study NCT03170128 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient physical therapy in addition to standard follow-up visits
Description: Patients in Group 1 will be given a prescription for outpatient physical therapy.
Study NCT03886207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ginger powder footbath
Description: 38-40° C warm water footbath with an additive of dried ginger powder reaching up to mid-calf level, as practiced in anthroposophic medicine
Study NCT03886207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: warm water only footbath
Description: 38-40° C warm water footbath without any additive reaching up to mid-calf level